Sorrento is an antibody-centric, clinical stage biopharmaceutical company focused on the discovery and development of safe and effective immunotherapies for oncology and autoimmune/inflammation diseases. Sorrento’s lead programs consist of four Phase III BioSimilar/BioBetter antibodies, which address an established market of more than $13 billion, and two Phase I CAR-T programs for treatment of solid tumors. Sorrento also is advancing a portfolio of adoptive cellular therapies, immuno-oncology mAbs, and antibody drug conjugates (ADCs). Sorrento partnered with City of Hope to form LA Cell subsidiary to focus on developing cell-internalizing mAbs against undruggable intracellular targets.